Literature DB >> 25862845

Formamidinodoxorubicins are more potent than doxorubicin as apoptosis inducers in human breast cancer cells.

Agnieszka Marczak1, Marta Denel-Bobrowska1, Małgorzata Łukawska2, Irena Oszczapowicz3.   

Abstract

BACKGROUND/AIM: The ability of five formamidinodoxorubicins to induce apoptosis of MCF-7 breast cancer cells was tested. All these compounds were modified at C-3' and contain a formamidine group (-N=CH-NRR), with the rest of the cyclic secondary amine (HNRR) of a gradually increasing ring size.
MATERIALS AND METHODS: Cytotoxicity was assessed using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. To analyze apoptosis, double staining using fluorescence probes Hoechst 33258/propidium iodide (PI) and annexin V- Fluorescein isothiocyanate/PI was carried-out. Additionally, the TdT-mediated dUTP nick-end labelling test and activity of caspase 3 were determined.
RESULTS: The four tested derivatives displayed a significant increase in antiproliferative activity in comparison to doxorubicin. All of the tested derivatives induced caspase-dependent apoptosis of MCF-7 cells.
CONCLUSION: DOX-F MOR and DOX-F PAZ analogs are more potent apoptosis inducers than doxorubicin. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Apoptosis; cytotoxicity; formamidine anthracyclines; necrosis

Mesh:

Substances:

Year:  2015        PMID: 25862845

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties.

Authors:  Andrey E Shchekotikhin; Lyubov G Dezhenkova; Vladimir B Tsvetkov; Yuri N Luzikov; Yulia L Volodina; Victor V Tatarskiy; Anastasia A Kalinina; Michael I Treshalin; Helen M Treshalina; Vladimir I Romanenko; Dmitry N Kaluzhny; Michael Kubbutat; Dominique Schols; Yves Pommier; Alexander A Shtil; Maria N Preobrazhenskaya
Journal:  Eur J Med Chem       Date:  2016-02-04       Impact factor: 6.514

2.  Chemical modification of melphalan as a key to improving treatment of haematological malignancies.

Authors:  Arkadiusz Gajek; Anastazja Poczta; Małgorzata Łukawska; Violetta Cecuda-Adamczewska; Joanna Tobiasz; Agnieszka Marczak
Journal:  Sci Rep       Date:  2020-03-11       Impact factor: 4.379

3.  MiR-122 Reverses the Doxorubicin-Resistance in Hepatocellular Carcinoma Cells through Regulating the Tumor Metabolism.

Authors:  Chenwei Pan; Xiaodong Wang; Keqing Shi; Yi Zheng; Jie Li; Yongping Chen; Lingxiang Jin; Zhenzhen Pan
Journal:  PLoS One       Date:  2016-05-03       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.